First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors
L.L. Siu, M.E. Gutierrez, L. Pudelko, K. Ruth, M.A.F.N. Filho, R. Zaynagetdinov, P. Hu, T. Kitzing, B.K. Guenhan, I. Durutovic, M. McKean · 2026
Read First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors by L.L. Siu, M.E. Gutierrez, L. Pudelko, K. Ruth, M.A.F.N. Filho, R. Zaynagetdinov, P. Hu, T. Kitzing, B.K. Guenhan, I. Durutovic, M. McKean (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13185761.txt.
Description
Siu and co-authors report the first human trial of a drug that blocks two adenosine receptors to free the immune system against tumors, in work published in 2026. Surname only is used for the lead author because the head gives initials. Fifteen patients with advanced solid tumors took the drug twice daily across four dose levels.
Two patients hit dose limiting side effects, one on a muscle enzyme and one on a pancreas enzyme. Tiredness and nausea were the most common complaints. Three patients held stable disease, and one stayed stable for over a year at the lowest dose. No tumors shrank. A middle dose was picked for expansion, though the study closed early, the authors report.
Catalog record
| CREATOR | L.L. Siu, M.E. Gutierrez, L. Pudelko, K. Ruth, M.A.F.N. Filho, R. Zaynagetdinov, P. Hu, T. Kitzing, B.K. Guenhan, I. Durutovic, M. McKean |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |